Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitors

BACKGROUND & AIMS: Immune checkpoint inhibitors (ICIs) play an increasingly important role in the treatment of primary liver cancer (PLC). Some patients with PLC experience symptoms of splenomegaly. Splenomegaly may affect the efficacy of ICIs due to an imbalance of the immune microenvironment....

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Lu‐Shan, Hu, Cheng‐Yi, Cui, Hao, Li, Rui‐Ning, Hong, Chang, Li, Qi‐Mei, Huang, Chao‐Yi, Dong, Zhong‐Yi, Zhu, Hong‐Bo, Liu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761067/
https://www.ncbi.nlm.nih.gov/pubmed/35599583
http://dx.doi.org/10.1002/cam4.4818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761067/
https://www.ncbi.nlm.nih.gov/pubmed/35599583
http://dx.doi.org/10.1002/cam4.4818

Ejemplares similares